

05 January 2009

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



Quarry House
Quarry Hill
Leeds
LS2 7UE

Tel: [REDACTED]

Dear Carole

Patient Access Scheme for lenalidomide for the treatment of multiple myeloma

I am writing to confirm the Department of Health's position on the Patient Access Scheme (PAS) arrangements that have been proposed by Celgene for lenalidomide in the treatment of multiple myeloma. The Department is content for NICE to consider the lenalidomide scheme as part of its technology appraisal of the drug.

Yours sincerely

[REDACTED]
[REDACTED]
[REDACTED] Pharmacy and Industry Group